Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Challenge Study of Bordetella Pertussis Colonisation and Delayed Antibiotic Therapy
NCT05847322Completed
- Sponsor
- University of Southampton
- Start
- Dec 2022
- Primary completion
- Sep 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label trial of Bordetella pertussis B1917 in pertussis (2 arms), sponsored by University of Southampton. Primary endpoints: Incidence of solicited adverse events at 6 weeks, Incidence of unsolicited adverse events at 6 weeks and 2 more. Started Dec 2022; status: completed.
02
Drugs
Bordetella pertussis B1917
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT05847322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847322.